Lambert-Messerlian GM - Search Results

1

Proteomic analysis of maternal serum in down syndrome: identification of novel protein biomarkers.

Nagalla SR, Canick JA, Jacob T, Schneider KA, Reddy AP, Thomas A, Dasari S, Lu X, Lapidus JA, Lambert-Messerlian GM, Gravett MG, Roberts CT Jr, Luthy D, Malone FD, D'Alton ME. Nagalla SR, et al. J Proteome Res. 2007 Apr;6(4):1245-57. doi: 10.1021/pr060539h. Epub 2007 Mar 21. J Proteome Res. 2007. PMID: 17373838

2

Prenatal screening for Down syndrome: current and future methods.

Canick JA, Saller DN Jr, Lambert-Messerlian GM. Canick JA, et al. Clin Lab Med. 2003 Jun;23(2):395-411. doi: 10.1016/s0272-2712(03)00025-8. Clin Lab Med. 2003. PMID: 12848451 Review.

3

Clinical application of inhibin a measurement: prenatal serum screening for Down syndrome.

Lambert-Messerlian GM, Canick JA. Lambert-Messerlian GM, et al. Semin Reprod Med. 2004 Aug;22(3):235-42. doi: 10.1055/s-2004-831899. Semin Reprod Med. 2004. PMID: 15319826 Review.

4

Placenta growth factor levels in second-trimester maternal serum in Down syndrome pregnancy and in the prediction of preeclampsia.

Lambert-Messerlian GM, Canick JA. Lambert-Messerlian GM, et al. Prenat Diagn. 2004 Nov;24(11):876-80. doi: 10.1002/pd.998. Prenat Diagn. 2004. PMID: 15565562

5

A summary analysis of Down syndrome markers in the late first trimester.

Palomaki GE, Lambert-Messerlian GM, Canick JA. Palomaki GE, et al. Adv Clin Chem. 2007;43:177-210. Adv Clin Chem. 2007. PMID: 17249384 Review.

6

Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters.

Zhang J, Lambert-Messerlian G, Palomaki GE, Canick JA. Zhang J, et al. Prenat Diagn. 2011 Jun;31(6):583-8. doi: 10.1002/pd.2755. Epub 2011 Apr 11. Prenat Diagn. 2011. PMID: 21480302

7

Examination of the pregnancy-associated plasma protein-A assay on the Beckman Coulter Access(®) platform: suitability for use in first trimester Down's syndrome screening.

Lambert-Messerlian G, Palomaki GE, Canick JA. Lambert-Messerlian G, et al. J Med Screen. 2010;17(3):109-13. doi: 10.1258/jms.2010.010041. J Med Screen. 2010. PMID: 20956719

8

Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy.

Farina A, LeShane ES, Lambert-Messerlian GM, Canick JA, Lee T, Neveux LM, Palomaki GE, Bianchi DW. Farina A, et al. Clin Chem. 2003 Feb;49(2):239-42. doi: 10.1373/49.2.239. Clin Chem. 2003. PMID: 12560345

9

Comparison of serum markers in first-trimester down syndrome screening.

Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, Malone FD, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Saade GR, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME; First and Second Trimester Evaluation of Risk (FASTER) Trial Research Consortium. Canick JA, et al. Obstet Gynecol. 2006 Nov;108(5):1192-9. doi: 10.1097/01.AOG.0000241095.19638.f2. Obstet Gynecol. 2006. PMID: 17077242

10

Feasibility of using plasma rather than serum in first and second trimester multiple marker Down's syndrome screening.

Lambert-Messerlian GM, Palomaki GE, Eklund EE, Kloza EM, Neveux LM, Phipps MG, Canick JA. Lambert-Messerlian GM, et al. J Med Screen. 2012 Dec;19(4):164-70. doi: 10.1258/jms.2012.012086. Epub 2012 Dec 31. J Med Screen. 2012. PMID: 23277614

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters